SecProbe.io

Filing text and metadata
Intelligence Terminal Search Probe Scores Topics IPO Watchlist Monthly Activity About API

SEC Comment Letter for AMERICAN INTERNATIONAL HOLDINGS CORP. (AMIH) (CIK 0001300524) — Apr 26, 2022

AMERICAN INTERNATIONAL HOLDINGS CORP. (AMIH) (CIK 0001300524)
Date: April 26, 2022 · CIK: 0001300524 · Accession: 0000000000-22-004431

AI Filing Summary & Sentiment

File numbers found in text: 333-264411

Date
April 26, 2022
Author
Not clearly detected
Form
UPLOAD
Company
AMERICAN INTERNATIONAL HOLDINGS CORP. (AMIH) (CIK 0001300524)

Letter

United States securities and exchange commission logo April 26, 2022 Jacob Cohen Chief Executive Officer AMERICAN INTERNATIONAL HOLDINGS CORP. 7950 Legacy Drive, Suite 400 Plano, Texas 75024 Re:AMERICAN INTERNATIONAL HOLDINGS CORP. Registration Statement on Form S-1 Filed April 21, 2022 File No. 333-264411 Dear Mr. Cohen: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Daniel Crawford at 202-551-7767 with any questions. Sincerely, Division of Corporation Finance Office of Life Sciences cc: David Loev, Esq.

Show Raw Text
United States securities and exchange commission logo
April 26, 2022
Jacob Cohen
Chief Executive Officer
AMERICAN INTERNATIONAL HOLDINGS CORP.
7950 Legacy Drive, Suite 400
Plano, Texas 75024
Re:AMERICAN INTERNATIONAL HOLDINGS CORP.
Registration Statement on Form S-1
Filed April 21, 2022
File No. 333-264411
Dear Mr. Cohen:
            This is to advise you that we have not reviewed and will not review your registration
statement.
            Please refer to Rules 460 and 461 regarding requests for acceleration.  We remind you
that the company and its management are responsible for the accuracy and adequacy of their
disclosures, notwithstanding any review, comments, action or absence of action by the staff.
            Please contact Daniel Crawford at 202-551-7767 with any questions.
Sincerely,
Division of Corporation Finance
Office of Life Sciences
cc:       David Loev, Esq.